Cooper Companies Inc., The (COO)

$90.2

-1.48

(-1.61%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Cooper Companies Inc., The

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 927.1M → 931.6M (in $), with an average increase of 0.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 85.3M → 81.2M (in $), with an average decrease of 2.4% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 27.1% return, outperforming this stock by 31.9%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 28.5% return, outperforming this stock by 40.8%

Performance

  • $90.17
    $92.05
    $90.20
    downward going graph

    0.03%

    Downside

    Day's Volatility :2.04%

    Upside

    2.01%

    downward going graph
  • $75.94
    $104.07
    $90.20
    downward going graph

    15.81%

    Downside

    52 Weeks Volatility :27.03%

    Upside

    13.33%

    downward going graph

Returns

PeriodCooper Companies Inc., TheSector (Health Care)Index (Russel 2000)
3 Months
-4.87%
1.7%
0.0%
6 Months
-71.39%
11.3%
0.0%
1 Year
-4.8%
5.4%
1.3%
3 Years
-11.92%
13.9%
-22.1%

Highlights

Market Capitalization
17.9B
Book Value
$38.73
Dividend Share
0.008
Dividend Yield
0.02%
Earnings Per Share (EPS)
1.46
PE Ratio
61.67
PEG Ratio
11.55
Wall Street Target Price
108.36
Profit Margin
7.93%
Operating Margin TTM
16.43%
Return On Assets TTM
2.69%
Return On Equity TTM
3.87%
Revenue TTM
3.7B
Revenue Per Share TTM
18.5
Quarterly Revenue Growth YOY
8.5%
Gross Profit TTM
2.4B
EBITDA
882.9M
Diluted Eps TTM
1.46
Quarterly Earnings Growth YOY
-0.04
EPS Estimate Current Year
3.55
EPS Estimate Next Year
3.95
EPS Estimate Current Quarter
0.78
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Cooper Companies Inc., The(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
11
10
12
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.13%

Current $90.20
Target $108.36

Company Financials

FY18Y/Y Change
Revenue
2.5B
↑ 18.41%
Net Income
139.9M
↓ 62.48%
Net Profit Margin
5.52%
↓ 11.91%
FY19Y/Y Change
Revenue
2.7B
↑ 4.76%
Net Income
466.7M
↑ 233.6%
Net Profit Margin
17.59%
↑ 12.07%
FY20Y/Y Change
Revenue
2.4B
↓ 8.39%
Net Income
238.4M
↓ 48.92%
Net Profit Margin
9.81%
↓ 7.78%
FY21Y/Y Change
Revenue
2.9B
↑ 20.22%
Net Income
2.9B
↑ 1135.19%
Net Profit Margin
100.76%
↑ 90.95%
FY22Y/Y Change
Revenue
3.3B
↑ 13.2%
Net Income
385.8M
↓ 86.9%
Net Profit Margin
11.66%
↓ 89.1%
FY23Y/Y Change
Revenue
3.6B
↑ 8.61%
Net Income
294.2M
↓ 23.74%
Net Profit Margin
8.19%
↓ 3.47%
Q4 FY22Q/Q Change
Revenue
848.1M
↑ 0.56%
Net Income
65.6M
↓ 33.33%
Net Profit Margin
7.73%
↓ 3.94%
Q1 FY23Q/Q Change
Revenue
858.5M
↑ 1.23%
Net Income
84.6M
↑ 28.96%
Net Profit Margin
9.85%
↑ 2.12%
Q2 FY23Q/Q Change
Revenue
877.4M
↑ 2.2%
Net Income
39.8M
↓ 52.96%
Net Profit Margin
4.54%
↓ 5.31%
Q3 FY23Q/Q Change
Revenue
930.2M
↑ 6.02%
Net Income
85.3M
↑ 114.32%
Net Profit Margin
9.17%
↑ 4.63%
Q4 FY23Q/Q Change
Revenue
927.1M
↓ 0.33%
Net Income
84.5M
↓ 0.94%
Net Profit Margin
9.11%
↓ 0.06%
Q1 FY24Q/Q Change
Revenue
931.6M
↑ 0.49%
Net Income
81.2M
↓ 3.91%
Net Profit Margin
8.72%
↓ 0.39%
FY18Y/Y Change
Total Assets
6.1B
↑ 25.81%
Total Liabilities
2.8B
↑ 66.68%
FY19Y/Y Change
Total Assets
6.3B
↑ 2.65%
Total Liabilities
2.6B
↓ 5.67%
FY20Y/Y Change
Total Assets
6.7B
↑ 7.38%
Total Liabilities
2.9B
↑ 10.08%
FY21Y/Y Change
Total Assets
9.6B
↑ 42.58%
Total Liabilities
2.7B
↓ 8.53%
FY22Y/Y Change
Total Assets
11.5B
↑ 19.63%
Total Liabilities
4.3B
↑ 62.06%
FY23Y/Y Change
Total Assets
11.7B
↑ 1.45%
Total Liabilities
4.1B
↓ 4.86%
Q4 FY22Q/Q Change
Total Assets
11.5B
↓ 0.52%
Total Liabilities
4.3B
↓ 3.39%
Q1 FY23Q/Q Change
Total Assets
11.6B
↑ 0.6%
Total Liabilities
4.2B
↓ 2.14%
Q2 FY23Q/Q Change
Total Assets
11.5B
↓ 0.19%
Total Liabilities
4.2B
↓ 1.51%
Q3 FY23Q/Q Change
Total Assets
11.7B
↑ 1.37%
Total Liabilities
4.2B
↑ 0.18%
Q4 FY23Q/Q Change
Total Assets
11.7B
↓ 0.33%
Total Liabilities
4.1B
↓ 1.46%
Q1 FY24Q/Q Change
Total Assets
12.0B
↑ 3.21%
Total Liabilities
4.3B
↑ 5.58%
FY18Y/Y Change
Operating Cash Flow
668.9M
↑ 12.69%
Investing Cash Flow
-1.5B
↑ 297.98%
Financing Cash Flow
844.4M
↓ 470.51%
FY19Y/Y Change
Operating Cash Flow
713.2M
↑ 6.62%
Investing Cash Flow
-351.3M
↓ 76.85%
Financing Cash Flow
-351.4M
↓ 141.62%
FY20Y/Y Change
Operating Cash Flow
486.6M
↓ 31.77%
Investing Cash Flow
-364.5M
↑ 3.76%
Financing Cash Flow
-95.5M
↓ 72.82%
FY21Y/Y Change
Operating Cash Flow
738.6M
↑ 51.79%
Investing Cash Flow
-450.3M
↑ 23.54%
Financing Cash Flow
-311.4M
↑ 226.07%
FY22Y/Y Change
Operating Cash Flow
692.4M
↓ 6.26%
Investing Cash Flow
-1.8B
↑ 306.66%
Financing Cash Flow
1.2B
↓ 483.33%
FY23Y/Y Change
Operating Cash Flow
607.5M
↓ 12.26%
Investing Cash Flow
-449.0M
↓ 75.48%
Financing Cash Flow
-173.9M
↓ 114.57%
Q4 FY22Q/Q Change
Operating Cash Flow
130.7M
↓ 50.47%
Investing Cash Flow
-99.7M
↑ 114.41%
Financing Cash Flow
-134.1M
↓ 63.63%
Q1 FY23Q/Q Change
Operating Cash Flow
166.6M
↑ 27.47%
Investing Cash Flow
-113.3M
↑ 13.64%
Financing Cash Flow
-77.6M
↓ 42.13%
Q2 FY23Q/Q Change
Operating Cash Flow
124.2M
↓ 25.45%
Investing Cash Flow
-82.0M
↓ 27.63%
Financing Cash Flow
-46.8M
↓ 39.69%
Q3 FY23Q/Q Change
Operating Cash Flow
142.5M
↑ 14.73%
Investing Cash Flow
-288.2M
↑ 251.46%
Financing Cash Flow
-43.0M
↓ 8.12%
Q4 FY23Q/Q Change
Operating Cash Flow
174.2M
↑ 22.25%
Investing Cash Flow
-160.8M
↓ 44.21%
Financing Cash Flow
-6.5M
↓ 84.88%

Technicals Summary

Sell

Neutral

Buy

Cooper Companies Inc., The is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cooper Companies Inc., The
Cooper Companies Inc., The
-10.58%
-71.39%
-4.8%
-11.92%
28.17%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-4.26%
40.66%
27.13%
29.92%
117.28%
Resmed Inc.
Resmed Inc.
-4.93%
30.8%
-18.9%
-12.86%
79.74%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.24%
-8.51%
-10.39%
-9.17%
-1.52%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-0.68%
7.75%
8.05%
19.64%
215.5%
Alcon Ag
Alcon Ag
-4.1%
12.21%
10.64%
4.52%
37.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cooper Companies Inc., The
Cooper Companies Inc., The
61.67
61.67
11.55
3.55
0.04
0.03
0.0
38.73
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
68.07
68.07
7.13
6.28
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
30.5
30.5
1.75
7.4
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
53.75
53.75
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
49.52
49.52
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
41.2
41.2
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cooper Companies Inc., The
Cooper Companies Inc., The
Buy
$17.9B
28.17%
61.67
7.93%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$133.8B
117.28%
68.07
27.16%
Resmed Inc.
Resmed Inc.
Buy
$27.1B
79.74%
30.5
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.7B
-1.52%
53.75
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$28.6B
215.5%
49.52
20.12%
Alcon Ag
Alcon Ag
Buy
$39.9B
37.47%
41.2
10.3%

Institutional Holdings

  • Vanguard Group Inc

    11.54%

  • BlackRock Inc

    8.77%

  • Veritas Asset Management LLP

    4.50%

  • State Street Corporation

    4.26%

  • T. Rowe Price Investment Management,Inc.

    3.69%

  • Kayne Anderson Rudnick Investment Management LLC

    3.50%

Corporate Announcements

  • Cooper Companies Inc., The Dividends March,2023

    In the quarter ending March,2023. Cooper Companies Inc., The has declared dividend of $0.03

    Read More

Company Information

company overview the cooper companies, inc. ("cooper"​) is a global medical device company publicly traded on the nyse euronext (nyse:coo). cooper is dedicated to being a quality of life company™ with a focus on delivering shareholder value. cooper operates through two business units, coopervision and coopersurgical. coopervision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. coopersurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. headquartered in pleasanton, ca, cooper has approximately 9,000 employees with products sold in over 100 countries. for more information, please visit www.coopercos.com.

Organization
Cooper Companies Inc., The
Employees
15000
CEO
Mr. Albert G. White III
Industry
Health Technology

Discover More

FAQs